The Role of NK Cells in Hematological Malignancies

Dear Colleagues,

Natural killer (NK) cells possess the ability to rapidly lyse tumour cells and promote the anti-cancer activity of other immune cell types, including macrophages, CD8+ T cells and dendritic cells. Furthermore, the development of NK cell-based therapeutics is an area of intense pre-clinical and clinical research. Importantly for their utilization in patients, NK cell therapies are not associated with the severe toxicities that can be associated with T cell-based therapies.

Increased knowledge of the role of NK cells in hematological malignancies will provide new avenues for research and allow for improved utilization against tumour cells in the clinical setting. In this Special Issue, we invite investigators to contribute original research, as well as review articles, that address recent advances in NK cell function with regard to haematological malignancies. We welcome authors to submit manuscripts that provide novel insights on NK cell biology and therapeutic strategies including CAR-NK cells, cytokines, tumour-targeting antibodies, NK cell engagers, and checkpoint inhibitors.

Dr. Matthew Blunt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• NK cells
• lymphoma
• multiple myeloma
• CLL
• AML
• leukaemia
• immunotherapy